• Publications
  • Influence
Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment.
Injection drug use was associated with significantly increased hazard ratios in users of opioids and cocaine/amphetamine and psychiatric comorbidity was not associated with increased mortality. Expand
Changes in the diagnosed incidence of early onset schizophrenia over four decades
The diagnosed incidence of early onset schizophrenia (EOS) from 1971 to 2010 is studied to explore changes in the diagnosed incidence. Expand
The heterogeneity of the depressive syndrome: when numbers get serious
The current criteria for major depression (1) have been criticized for the heterogeneity of the clinical syndrome they define. This has led to suggestions of alternative classifications, mostExpand
Increasing mortality gap for patients diagnosed with schizophrenia over the last three decades — A Danish nationwide study from 1980 to 2010
On average, patients with schizophrenia die younger than the general population, independent of intentional self-harm as cause of death. Expand
Relationships over time of subjective and objective elements of recovery in persons with schizophreni
Results are consistent with conceptualizations of recovery as a complex process and suggest that while there may be identifiably different domains, changes in subjective and objective domains may influence one another. Expand
Mortality following treatment for cannabis use disorders: predictors and causes.
Following exclusion of those with secondary use of opioids, cocaine, amphetamine, or injection drug use, SMRs for all causes of death remained significantly elevated except for homicide/violence, underlines the need to address mortality risk associated with cannabis use disorders. Expand
Second‐generation antipsychotic effect on cognition in patients with schizophrenia—a meta‐analysis of randomized clinical trials
To investigate the effect of second‐generation antipsychotics on cognitive function in patients diagnosed with schizophrenia or schizoaffective disorder.
Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort
RIS-LAI was not superior to FGA-LAIs regarding time to psychiatric hospitalization, all-cause discontinuation, and duration of hospitalization and these findings require consideration when making treatment choices. Expand
Schizophrenia, antipsychotics and risk of hip fracture: A population-based analysis
Several factors, including complex psychopharmacological treatment, contribute in the prediction of hip fracture in large populations, and preventive strategies should focus attention to severely ill patients with high likelihood of a receiving complex Psychopharmacologic treatment and high doses of antipsychotics. Expand
Risk factors for conversion from unipolar psychotic depression to bipolar disorder
Risk factors associated with diagnostic conversion from PD to BD are identified and implications for the choice of treatment are identified. Expand